Early results presented at CROI 2017 show the potential for bictegravir to be an important antiretroviral.
48-week results from a phase 3 study comparing the NNRTI doravirine to boosted darunavir showed similar viral suppression and low rates of side effects.
Two oral presentations on a new integrase inhibitor bictegravir were included in the first session at CROI 2017 looking at new treatment and treatment strategies.
At CROI 2017, Richard Kroup, M.D., from NIAID provided an overview of the recent advances in antibody treatments for HIV prevention and treatment.
Here's a preview of some of the noteworthy HIV cure and treatment research being presented at CROI 2017 in Seattle.
An HIV cure research experiment that treated monkeys with a4b7 antibodies yielded unexpected and promising results.
In the quest for a cure for HIV, many different approaches are being tested, with many clinical trials underway in the U.S.
In the search for a cure, the antibody vedolizumab (Entyvio) will likely draw much interest for testing with HIV-positive people.
HIV cure researchers seek out markers that would allow the specific targeting of cells harboring latent HIV. Enter a new candidate: interferon-induced transmembrane protein 1 (IFITM1).
"Despite the challenges, gene therapy is a promising avenue in the quest for a cure," amfAR's Rowena Johnston, Ph.D., says.